natgillin/translations-raw huggingface dataset:
Olanzapine Teva is also effective in maintaining improvement in patients who have responded to an initial course of treatment.
Zdravilo Olanzapine Teva je prav tako učinkovito pri vzdrževanju izboljšanja stanja pri bolnikih, ki so se odzvali na začetno zdravljenje.
For more information about treatment with Olanzapine Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Olanzapine Teva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Two medicines are bioequivalent when produce the same levels of the active substance in the body.
Dve zdravili sta biološko enakovredni, kadar dosegata enake ravni zdravilne učinkovine v telesu.
This is a summary of the European public assessment report (EPAR) for Olanzapine Teva.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Olanzapine Teva.
This means that Olanzapine Teva is similar to ‘reference medicines' already authorised in the European Union (EU) called Zyprexa and Zyprexa Velotab.
To pomeni, da je podobno „referenčnima zdraviloma“, ki sta že odobrena v Evropski uniji (EU), in sicer zdraviloma Zyprexa in Zyprexa Velotab.
This disrupts signals transmitted between brain cells by ‘neurotransmitters', chemicals that allow nerve cells to communicate with each other.
S tem se prekine prenos signalov med možganskimi celicami prek živčnih prenašalcev, tj. kemičnih snovi, ki omogočajo komunikacijo med celicami.
What are the benefits and risks of Olanzapine Teva?
Kakšne so koristi in tveganja, povezani z zdravilom Olanzapine Teva?
Olanzapine Teva is also used to treat moderate to severe manic episodes (extremely high mood) in adults.
Zdravilo Olanzapine Teva se uporablja tudi za zdravljenje zmernih do hudih maničnih epizod (izjemno privzdignjenega razpoloženja) pri odraslih.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Olanzapine Teva.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Olanzapine Teva, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Because Olanzapine Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicines.
Ker je zdravilo Olanzapine Teva generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnima zdraviloma.
Because Olanzapine Teva is a generic medicine and is bioequivalent to the reference medicines, its benefit and risk are taken as being the same as those of the reference medicines.
Ker je zdravilo Olanzapine Teva generično zdravilo in je biološko enakovredno referenčnima zdraviloma, se šteje, da ima enake koristi in tveganja kot referenčni zdravili.
The CHMP concluded that, in accordance with EU requirements, Olanzapine Teva has been shown to have comparable quality and to be bioequivalent to Zyprexa and Zyprexa Velotab.
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Olanzapine Teva primerljivo raven kakovosti kot zdravili Zyprexa in Zyprexa Velotab ter da jima je biološko enakovredno.
Olanzapine Teva is a ‘generic medicine'.
Olanzapine Teva je „generično zdravilo“.
Other information about Olanzapine Teva
Druge informacije o zdravilu Olanzapine Teva
The active substance in Olanzapine Teva, olanzapine, is an antipsychotic medicine.
Zdravilna učinkovina zdravila Olanzapine Teva, olanzapin, je antipsihotično zdravilo.
The orodispersible tablets, which can be used as an alternative to the tablets, are taken by being placed on the tongue, where they disintegrate quickly in the saliva, or by mixing them in water before swallowing.
Razpon odmerkov je običajno od 5 do 20 mg na dan. Orodisperzibilne tablete, ki se lahko uporabijo kot alternativa tabletam, se zaužijejo tako, da se položijo na jezik, kjer jih slina hitro raztopi, ali tako, da se pred zaužitjem zmešajo z vodo.
The Committee recommended that Olanzapine Teva be given marketing authorisation.
Priporočil je, da se za zdravilo Olanzapine Teva odobri dovoljenje za promet.
Olanzapine Teva is a medicine containing the active substance olanzapine.
Olanzapine Teva je zdravilo, ki vsebuje zdravilno učinkovino olanzapin.
Therefore, the CHMP's view was that, as for Zyprexa and Zyprexa Velotab, the benefit outweighs the identified risk.
Zato meni, da so koristi, tako kot pri zdravilih Zyprexa in Zyprexa Velotab, večje od z njim povezanih tveganj.
Why has Olanzapine Teva been approved?
Zakaj je bilo zdravilo Olanzapine Teva odobreno?
Olanzapine Teva is used to treat adults with schizophrenia.
Zdravilo Olanzapine Teva se uporablja za zdravljenje shizofrenije.
How has Olanzapine Teva been studied?
Kako je bilo zdravilo Olanzapine Teva raziskano?
What is Olanzapine Teva?
Kaj je zdravilo Olanzapine Teva?
What is Olanzapine Teva used for?
Za kaj se zdravilo Olanzapine Teva uporablja?
How is Olanzapine Teva used?
Kako se zdravilo Olanzapine Teva uporablja?
How does Olanzapine Teva work?
Kako zdravilo Olanzapine Teva deluje?
The marketing authorisation holder of SoliCol D3 shall provide evidence that the manufacturing process complies with the requirements of Commission Directive 2003/94/EC laying down the principles and guidelines of Good Manufacturing Practice (GMP) as provided for in Article 8(3) of Directive 2001/83/EC.
Za preklic začasnega umika dovoljenj za promet z zdravilom SoliCol D3 morajo pristojni organi zagotoviti, da je/so imetnik(-i) dovoljenj(a) za promet z zdravilom izpolnil(-i) spodnje pogoje: Imetnik dovoljenja za promet z zdravilom SoliCol D3 mora predložiti dokaz, da je postopek izdelave v skladu z zahtevami Direktive Komisije 2003/94/ES o določitvi načel in smernic dobre proizvodne prakse, kot je določeno v členu 8(3) Direktive 2001/83/ES.
Annex III Conditions for lifting the suspension of the marketing authorisation(s)
Priloga III
Over 70% of those given Erelzi (186 of 264 patients) and roughly 72% of those given Enbrel (191 of 267) had at least 75% reduction in their symptom score after 12 weeks of treatment, which was the main measure of effectiveness.
Pri več kot 70 % bolnikov, ki so prejemali zdravilo Erelzi (186 od 264 bolnikov) in pri približno 72 % bolnikov, ki so prejemali zdravilo Enbrel (191 od 267), je po 12 tednih zdravljenja prišlo do vsaj 75-odstotnega zmanjšanja simptomov, kar je bilo glavno merilo učinkovitosti.
This means that Erelzi is highly similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU).
To pomeni, da je zelo podobno biološkemu zdravilu (t. i. „referenčnemu zdravilu“), ki je že odobreno v Evropski uniji (EU).
What measures are being taken to ensure the safe and effective use of Erelzi?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Erelzi?
In adults, the usual recommended dose is 25 mg twice a week or 50 mg once a week.
Pri odraslih je priporočeni odmerek 25 mg dvakrat tedensko ali 50 mg enkrat tedensko.
The full EPAR for Erelzi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Erelzi je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
In children, the dose will depend on body weight.
Pri otrocih je odmerek odvisen od telesne mase.
The educational materials also include a reminder that Erelzi is not for use in children and adolescents who weigh less than 62.5 kg.
Izobraževalno gradivo vključuje tudi opomnik, da zdravilo Erelzi ni namenjeno uporabi pri otrocih in mladostnikih, ki tehtajo manj kot 62,5 kg.
This is a summary of the European public assessment report (EPAR) for Erelzi.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Erelzi.
It is not intended to provide practical advice on how to use Erelzi.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
The most common side effects with etanercept (seen in more than 1 patient in 10) are injection-site reactions (including bleeding, redness, itching, pain and swelling) and infections (including colds, and lung, bladder and skin infections).
Najpogostejši neželeni učinki zdravila Erelzi (opaženi pri več kot 1 bolniku od 10) so reakcije na mestu injiciranja (vključno s krvavitvami, rdečico, srbečico, bolečino in otekanjem) in okužbe (vključno s prehladi ter vnetji pljuč, mehurja in kože).
What benefits of Erelzi have been shown in studies?
Kakšne koristi je zdravilo Erelzi izkazalo v študijah?
Erelzi is mostly used when these conditions are severe or moderately severe, or when other treatments have not worked well enough or cannot be used.
Zdravilo Erelzi se uporablja predvsem za huda do srednje huda bolezenska stanja ali kadar druge vrste zdravljenja niso dovolj učinkovite ali se ne smejo uporabljati.
Erelzi is an anti-inflammatory medicine for treating the following diseases:
Erelzi je protivnetno zdravilo za zdravljenje naslednjih bolezni:
Erelzi must not be used in patients who have or are at risk of sepsis (when bacteria and toxins circulate in the blood and start to damage the organs), or in patients with active infections.
Zdravila Erelzi ne smejo jemati bolniki, ki imajo sepso ali pri katerih obstaja nevarnost sepse (kadar bakterije in toksini krožijo v krvi in poškodujejo organe), ali bolniki z aktivnimi okužbami.
Other information about Erelzi
Druge informacije o zdravilu Erelzi
What is Erelzi and what is it used for?
Kaj je zdravilo Erelzi in za kaj se uporablja?
The Committee recommended that Erelzi be given marketing authorisation.
Priporočil je, da se za zdravilo Erelzi izda dovoljenje za promet.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements for biosimilar medicines, Erelzi has been shown to have a comparable quality, safety and effectiveness to Enbrel.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU glede podobnih bioloških zdravil dokazano, da je zdravilo Erelzi po kakovosti, varnosti in učinkovitosti primerljivo zdravilu Enbrel.
What are the risks associated with Erelzi?
Kakšna tveganja so povezana z zdravilom Erelzi?
Erelzi is not for use in children who need doses other than 25 or 50 mg (e.g. those weighing less than 62.5 kg), because it is only available in these doses; an alternative product should be used in such children.
Zdravilo Erelzi ni namenjeno za uporabo pri otrocih, ki potrebujejo odmerke, ki ne zajemajo 25 ali 50 mg (npr. otroci, ki tehtajo manj kot 62,5 kg), ker je na voljo samo v teh odmerkih.
The company that markets Erelzi will provide educational material for doctors expected to prescribe the product to teach patients how to use the pre-filled pen correctly and a special alert card for patients so they can recognise serious side effects and know when to seek urgent attention from their doctor.
Družba, ki trži zdravilo Erelzi, bo zagotovila izobraževalno gradivo za zdravnike, ki naj bi ga predpisovali, da bodo bolnike poučili o pravilni uporabi napolnjenega peresnika, in opozorilno kartico za bolnike, da lahko prepoznajo resne neželene učinke in vedo, kdaj poiskati nujno zdravniško pomoč.
Patients developing a serious infection should stop Erelzi treatment.
Bolniki, pri katerih se pojavi resna okužba, morajo zdravilo Erelzi prenehati jemati.
By blocking TNF, etanercept reduces the inflammation and other symptoms of the diseases.
Etanercept z zaviranjem TNF zmanjša vnetje in blaži druge simptome bolezni.
The active substance in Erelzi, etanercept, is a protein that has been designed to block the activity of a substance called tumour necrosis factor alpha (TNF).
Zdravilna učinkovina v zdravilu Erelzi, etanercept, je beljakovina, katere namen je zavirati delovanje snovi, ki se imenuje dejavnik tumorske nekroze alfa (TNF).
Because Erelzi is a biosimilar medicine, the studies on effectiveness and safety of etanercept carried out with Enbrel do not all need to be repeated for Erelzi.
Zdravilo Erelzi je „podobno biološko zdravilo“, zato vseh študij o učinkovitosti in varnosti etanercepta, izvedenih z zdravilom Enbrel, z zdravilom Erelzi ni treba ponavljati.
Treatment is started and supervised by specialised doctors with experience in diagnosing and treating the diseases Erelzi is used for.
Zdravljenje začne in nadzoruje zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem bolezni, za katere se uporablja zdravilo Erelzi.
Treatment with 50 mg twice a week can also be used during the first 12 weeks of treatment for plaque psoriasis.
V prvih 12 tednih zdravljenja psoriaze v plakih se lahko 50-miligramski odmerek uporabi tudi dvakrat na teden.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Erelzi have also been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Erelzi upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
This substance is involved in causing inflammation and is found at high levels in patients with the diseases that Erelzi is used to treat.
Ta snov sodeluje pri nastanku vnetij in je v visokih koncentracijah prisotna pri bolnikih z boleznimi, za katerih zdravljenje se uporablja zdravilo Erelzi.
For more information about treatment with Erelzi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Erelzi preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Why is Erelzi approved?
Zakaj je bilo zdravilo Erelzi odobreno?
For practical information about using Erelzi, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Erelzi naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Erelzi is available as prefilled syringes and pens containing a solution for injection.
Zdravilo Erelzi je na voljo v obliki napolnjenih injekcijskih brizg in peresnikov, ki vsebujejo raztopino za injiciranje.
• certain forms of juvenile idiopathic arthritis (diseases causing inflammation in the joints, with first appearance in childhood or adolescence);
• določenih oblik juvenilnega idiopatskega artritisa (bolezni, ki povzročajo vnetje sklepov in se prvič pojavijo v otroštvu ali adolescenci);
For detailed information on the use of Erelzi in all conditions, see the summary of product characteristics (also part of the EPAR).
Več informacij o uporabi zdravila Erelzi za vsa obolenja je na voljo v povzetku glavnih značilnosti zdravila (ki je prav tako del EPAR).
Therefore, the CHMP's view was that, as for Enbrel, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Enbrel odtehtajo znana tveganja.
Erelzi contains the active substance etanercept and is a ‘biosimilar medicine'.
Zdravilo Erelzi vsebuje zdravilno učinkovino etanercept in je „podobno biološko zdravilo“.
For the full list of all side effects reported with Erelzi, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Erelzi, glejte navodilo za uporabo.
The reference medicine for Erelzi is Enbrel.
Referenčno zdravilo za zdravilo Erelzi je zdravilo Enbrel.
The injection is given under the skin and the patient or their carer can give the injection if they have been trained appropriately.
Bolniki in njihovi negovalci injekcijo lahko dajejo sami, če so bili ustrezno usposobljeni.
• rheumatoid arthritis (a disease causing inflammation of the joints) in adults, used with another medicine, methotrexate, or alone;
• revmatoidnega artritisa (bolezni, ki povzroča vnetje sklepov) pri odraslih, pri čemer se uporablja skupaj z metotreksatom ali samostojno;
Laboratory studies comparing Erelzi with Enbrel have shown that the active substance in Erelzi is highly similar to that in Enbrel in terms of structure, purity and biological activity.
Laboratorijske študije, v katerih so zdravilo Erelzi primerjali z zdravilom Enbrel, so pokazale, da je zdravilo Erelzi po zgradbi, čistosti in biološkem delovanju zelo podobno zdravilu Enbrel.
• psoriatic arthritis (psoriasis with inflammation of the joints) in adults and adolescents;
• psoriatičnega artritisa (psoriaze z vnetjem sklepov) pri odraslih in mladostnikih;
• plaque psoriasis (a disease causing red, scaly patches on the skin) in adults and children;
• psoriaze v plakih (bolezni, ki povzroča rdeče luskaste zaplate na koži) pri odraslih in otrocih;
• axial spondyloarthritis (a chronic inflammatory disease of the spine) in adults when there are no abnormalities seen on x-ray.
• aksialnega spondiloartritisa (kronične vnetne bolezni hrbtenice) pri odraslih, kadar bolezenske spremembe na rentgenskih slikah niso vidne.
How is Erelzi used?
Kako se zdravilo Erelzi uporablja?
• ankylosing spondylitis (a disease causing inflammation of the joints of the spine) in adults;
• ankilozirajočega spondilitisa (bolezni, ki povzroča vnetje sklepov v hrbtenici) pri odraslih;
How does Erelzi work?
Kako zdravilo Erelzi deluje?
Erelzi was also shown to be as effective as Enbrel in one main study involving 531 adults with plaque psoriasis.
V glavni študiji, ki je vključevala 531 odraslih s psoriazo v plakih, so dokazali tudi, da je zdravilo Erelzi enako učinkovito kot zdravilo Enbrel.
Studies were carried out to show that Erelzi produces similar levels of the active substance in the body to Enbrel.
Opravljena je bila študija, ki je pokazala, da je količina zdravilne učinkovine v telesu pri zdravilu Erelzi podobna kot pri zdravilu Enbrel.
This summary was last updated in October 2016.
Povzetek je bil nazadnje posodobljen oktobra 2016.
This effect increases with higher doses and/or repeated treatments.
Ta učinek se povečuje s povečevanjem odmerka in/ali ponovljenimi zdravljenji.
People must not eat, drink or smoke while using the medicine.
Ljudje med uporabo zdravila ne smejo jesti, piti ali kaditi.
Heavily contaminated clothes should be changed immediately and washed before re-use.
Močno kontaminirana oblačila je treba takoj preobleči in jih pred ponovno uporabo oprati.
In each location 20 test groups were compared to 12 control groups treated with flumethrin (another medicine effective against parasites).
Na vsaki lokaciji so 20 testnih skupin primerjali z 12 kontrolnimi skupinami, zdravljenimi s flumetrinom (drugim zdravilom, ki deluje proti parazitom).
The full EPAR for VarroMed can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila VarroMed je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
The dose is adjusted to the colony size.
Odmerek se prilagodi velikosti kolonije.
Treatment should be given in the late afternoon or evening when bees are less likely to be flying.
Zdravljenje je treba izvajati pozno popoldne ali zvečer, ko čebele manj pogosto izletajo.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that VarroMed's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila VarroMed večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
This is a summary of the European public assessment report (EPAR) for VarroMed.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo VarroMed.
The average effectiveness of VarroMed to kill mites (measured by the number of dead mites found at the bottom of the hive) was 88% for winter, 92% for spring and 85% for autumn treatments.
Povprečna učinkovitost zdravila VarroMed pri uničevanju varoj (merjena s številom poginulih varoj, najdenih na dnu panja) je bila pri zimskem zdravljenju 88 %, pri spomladanskem 92 % in pri jesenskem 85 %.
The effectiveness of VarroMed was investigated in field studies in European countries with different climates, both continental climate and Mediterranean climate.
Učinkovitost zdravila VarroMed so preučevali v terenskih študijah v evropskih državah z različnimi podnebji, celinskim in sredozemskim.
The most common side effect with VarroMed (which may affect more than 1 in 10 bee colonies) is an increased number of deaths of worker bees.
Najpogostejši neželeni učinek zdravila VarroMed (ki lahko prizadene več kot 1 od 10 čebeljih kolonij) je povečano število smrti čebel delavk.
Varroa mite and honey bee mortality were monitored twice weekly for 4 weeks during treatment until one week after treatment.
Umrljivost varoj in medonosnih čebel so spremljali dvakrat tedensko v obdobju 4 tednov med zdravljenjem in en teden po zdravljenju.
People should avoid contact with the skin, eyes and mucous membranes (moist body surfaces such as lining of mouth).
Ljudje se morajo izogibati stiku s kožo, očmi in sluznicami (vlažnimi telesnimi površinami, kot je ustna sluznica).
The groups were treated during winter (in the absence of brood), spring and autumn (in the presence of brood) and included colonies of different sizes (5,000 to 30,000 bees) and different infestation levels.
Skupine so zdravili pozimi (v odsotnosti zalege), spomladi in jeseni (v prisotnosti zalege), vključevale pa so kolonije različnih velikosti (od 5 000 do 30 000 čebel) in različne stopnje infestacije.
VarroMed is intended to be used as part of an integrated varroa control programme, which includes other techniques.
Zdravilo VarroMed je namenjeno uporabi kot del integriranega programa zatiranja varoje, ki vključuje še druge tehnike.
In case of accidental spillage onto skin, the affected areas should be washed immediately with running water.
V primeru nenamernega razlitja po koži je treba prizadeta območja nemudoma izprati s tekočo vodo.
A significant mite infestation can lead to the collapse of a honey bee colony.
Znatna infestacija z varojo lahko privede do kolapsa kolonije medonosnih čebel.
People who are hypersensitive (allergic) to formic acid or oxalic acid should give the medicine with caution.
Ljudje, ki so preobčutljivi za (alergični na) mravljično kislino ali oksalno kislino, morajo zdravilo dajati previdno.
It can be used either as a single-dose treatment during the broodless period (winter treatment), or in the presence of brood (spring or autumn treatment) which will usually require repeated treatments.
Uporablja se lahko kot zdravljenje z enkratnim odmerkom v času brez zalege (zimsko zdravljenje) ali v prisotnosti zalege (spomladansko ali jesensko zdravljenje), kar običajno zahteva večkratno zdravljenje.
It is not intended to provide practical advice on how to use VarroMed.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
In case of accidental spillage into the eye(s) flush the eye(s) immediately with clear running water for 10 minutes.
V primeru nenamernega razlitja v oči je treba takoj 10 minut izpirati oči s čisto tekočo vodo.
What is VarroMed and what is it used for?
Kaj je zdravilo VarroMed in za kaj se uporablja?
Why is VarroMed approved?
Zakaj je bilo zdravilo VarroMed odobreno?
VarroMed is irritating to the skin and eyes.
Zdravilo VarroMed je dražilno za kožo in oči.
VarroMed oxalic acid dihydrate / formic acid
VarroMed oksalna kislina dihidrat/mravljična kislina
Children should be kept from contact with VarroMed.
Otroci ne smejo priti v stik z zdravilom VarroMed.
What benefits of VarroMed have been shown in studies?
Kakšne koristi je zdravilo VarroMed izkazalo v študijah?